APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Blood Products

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Human Blood Products Market Analysis and Forecast 2026-2032

30 December 2025203 pages

Choose your research edition.

Industry ResearchHuman Blood Products Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Blood Products Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Human Blood Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Blood Products Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Blood Products Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Human Blood Products market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Human Blood Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Human Blood Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Human Blood Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Human Blood Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Human Blood Products include Biotest, BPL, CSL, Grifols, Kedrion, KM Biologics, LFB Group, Octapharma and Boya Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Human Blood Products, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Blood Products, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Blood Products, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Blood Products revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Blood Products market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Human Blood Products revenue, projected growth trends, production technology, application and end-user industry.

Human Blood Products Segment by Company

Biotest

BPL

CSL

Grifols

Kedrion

KM Biologics

LFB Group

Octapharma

Boya Bio

Hualan Bio

Nanyue Bio

RAAS

Shuanglin Bio

CBPO

Tiantan Bio

Weiguang Bio

Takeda

Yuanda Shuyang

Human Blood Products Segment by Type

Immune Globulin

Coagulation Factor

Albumin

Other

Human Blood Products Segment by Application

Hospital

Retail Pharmacy

Other

Human Blood Products Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Blood Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Blood Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Blood Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Human Blood Products in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Human Blood Products company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Blood Products revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Blood Products Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immune Globulin Major Player Table 3. Coagulation Factor Major Player Table 4. Albumin Major Player Table 5. Other Major Player Table 6. Global Human Blood Products Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Retail Pharmacy Major Player Table 9. Other Major Player Table 10. Human Blood Products Industry Trends Table 11. Human Blood Products Industry Drivers Table 12. Human Blood Products Industry Opportunities and Challenges Table 13. Human Blood Products Industry Restraints Table 14. Global Human Blood Products Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Human Blood Products Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Human Blood Products Market Share by Region (2021-2026) Table 17. Global Human Blood Products Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Human Blood Products Market Share by Region (2027-2032) Table 19. Global Human Blood Products Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Human Blood Products Revenue Market Share by Players (2021-2026) Table 21. Global Human Blood Products Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Human Blood Products Key Players Headquarters & Area Served Table 23. Global Human Blood Products Players, Product Type & Application Table 24. Global Human Blood Products Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Human Blood Products by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Human Blood Products Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human Blood Products Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Human Blood Products Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Human Blood Products Revenue Market Share by Type (2021-2026) Table 31. Global Human Blood Products Revenue Market Share by Type (2027-2032) Table 32. Global Human Blood Products Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Human Blood Products Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Human Blood Products Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Human Blood Products Revenue Market Share by Application (2021-2026) Table 36. Global Human Blood Products Revenue Market Share by Application (2027-2032) Table 37. Biotest Company Information Table 38. Biotest Business Overview Table 39. Biotest Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Biotest Human Blood Products Product Portfolio Table 41. Biotest Recent Development Table 42. BPL Company Information Table 43. BPL Business Overview Table 44. BPL Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. BPL Human Blood Products Product Portfolio Table 46. BPL Recent Development Table 47. CSL Company Information Table 48. CSL Business Overview Table 49. CSL Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. CSL Human Blood Products Product Portfolio Table 51. CSL Recent Development Table 52. Grifols Company Information Table 53. Grifols Business Overview Table 54. Grifols Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Grifols Human Blood Products Product Portfolio Table 56. Grifols Recent Development Table 57. Kedrion Company Information Table 58. Kedrion Business Overview Table 59. Kedrion Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Kedrion Human Blood Products Product Portfolio Table 61. Kedrion Recent Development Table 62. KM Biologics Company Information Table 63. KM Biologics Business Overview Table 64. KM Biologics Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. KM Biologics Human Blood Products Product Portfolio Table 66. KM Biologics Recent Development Table 67. LFB Group Company Information Table 68. LFB Group Business Overview Table 69. LFB Group Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. LFB Group Human Blood Products Product Portfolio Table 71. LFB Group Recent Development Table 72. Octapharma Company Information Table 73. Octapharma Business Overview Table 74. Octapharma Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Octapharma Human Blood Products Product Portfolio Table 76. Octapharma Recent Development Table 77. Boya Bio Company Information Table 78. Boya Bio Business Overview Table 79. Boya Bio Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Boya Bio Human Blood Products Product Portfolio Table 81. Boya Bio Recent Development Table 82. Hualan Bio Company Information Table 83. Hualan Bio Business Overview Table 84. Hualan Bio Human Blood Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Hualan Bio Human Blood Products Product Portfolio Table 86. Hualan Bio Recent Development Table 87. Nanyue Bio Company Information Table 88. Nanyue Bio Business Overview Table 89. Nanyue Bio Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Nanyue Bio Human Blood Products Product Portfolio Table 91. Nanyue Bio Recent Development Table 92. RAAS Company Information Table 93. RAAS Business Overview Table 94. RAAS Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. RAAS Human Blood Products Product Portfolio Table 96. RAAS Recent Development Table 97. Shuanglin Bio Company Information Table 98. Shuanglin Bio Business Overview Table 99. Shuanglin Bio Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Shuanglin Bio Human Blood Products Product Portfolio Table 101. Shuanglin Bio Recent Development Table 102. CBPO Company Information Table 103. CBPO Business Overview Table 104. CBPO Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. CBPO Human Blood Products Product Portfolio Table 106. CBPO Recent Development Table 107. Tiantan Bio Company Information Table 108. Tiantan Bio Business Overview Table 109. Tiantan Bio Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Tiantan Bio Human Blood Products Product Portfolio Table 111. Tiantan Bio Recent Development Table 112. Weiguang Bio Company Information Table 113. Weiguang Bio Business Overview Table 114. Weiguang Bio Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Weiguang Bio Human Blood Products Product Portfolio Table 116. Weiguang Bio Recent Development Table 117. Takeda Company Information Table 118. Takeda Business Overview Table 119. Takeda Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Takeda Human Blood Products Product Portfolio Table 121. Takeda Recent Development Table 122. Yuanda Shuyang Company Information Table 123. Yuanda Shuyang Business Overview Table 124. Yuanda Shuyang Human Blood Products Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Yuanda Shuyang Human Blood Products Product Portfolio Table 126. Yuanda Shuyang Recent Development Table 127. North America Human Blood Products Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Human Blood Products Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Human Blood Products Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Human Blood Products Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Human Blood Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Human Blood Products Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Human Blood Products Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Human Blood Products Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Human Blood Products Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Human Blood Products Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Human Blood Products Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Human Blood Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Human Blood Products Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Human Blood Products Revenue by Country (US$ Million) & (2027-2032) Table 141. China Human Blood Products Revenue by Type (2021-2026) & (US$ Million) Table 142. China Human Blood Products Revenue by Type (2027-2032) & (US$ Million) Table 143. China Human Blood Products Revenue by Application (2021-2026) & (US$ Million) Table 144. China Human Blood Products Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Human Blood Products Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Human Blood Products Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Human Blood Products Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Human Blood Products Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Human Blood Products Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Human Blood Products Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Human Blood Products Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Human Blood Products Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Human Blood Products Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Human Blood Products Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Human Blood Products Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Human Blood Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Human Blood Products Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Human Blood Products Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Human Blood Products Image Figure 2. Global Human Blood Products Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Blood Products Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immune Globulin Image Figure 5. Coagulation Factor Image Figure 6. Albumin Image Figure 7. Other Image Figure 8. Global Human Blood Products Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Human Blood Products Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Retail Pharmacy Image Figure 12. Other Image Figure 13. Global Human Blood Products Market Size (US$ Million) & (2021-2032) Figure 14. Global Human Blood Products Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Human Blood Products Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Human Blood Products Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Human Blood Products Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Human Blood Products Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Human Blood Products Revenue Market Share by Type (2021-2032) Figure 21. Global Human Blood Products Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Human Blood Products Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Human Blood Products Revenue Market Share by Application (2021-2032) Figure 24. North America Human Blood Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Human Blood Products Revenue Share by Type (2021-2032) Figure 26. North America Human Blood Products Revenue Share by Application (2021-2032) Figure 27. North America Human Blood Products Revenue Share by Country (2021-2032) Figure 28. United States Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Human Blood Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Human Blood Products Revenue Share by Type (2021-2032) Figure 33. Europe Human Blood Products Revenue Share by Application (2021-2032) Figure 34. Europe Human Blood Products Revenue Share by Country (2021-2032) Figure 35. Germany Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Human Blood Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Human Blood Products Revenue Share by Type (2021-2032) Figure 45. China Human Blood Products Revenue Share by Application (2021-2032) Figure 46. Asia Human Blood Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Human Blood Products Revenue Share by Type (2021-2032) Figure 48. Asia Human Blood Products Revenue Share by Application (2021-2032) Figure 49. Asia Human Blood Products Revenue Share by Region (2021-2032) Figure 50. Japan Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Human Blood Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Human Blood Products Revenue Share by Type (2021-2032) Figure 58. SAMEA Human Blood Products Revenue Share by Application (2021-2032) Figure 59. SAMEA Human Blood Products Revenue Share by Country (2021-2032) Figure 60. Brazil Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Human Blood Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Globulin
  • Coagulation Factor
  • Albumin
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Biotest
  • BPL
  • CSL
  • Grifols
  • Kedrion
  • KM Biologics
  • LFB Group
  • Octapharma
  • Boya Bio
  • Hualan Bio
  • Nanyue Bio
  • RAAS
  • Shuanglin Bio
  • CBPO
  • Tiantan Bio
  • Weiguang Bio
  • Takeda
  • Yuanda Shuyang

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Blood Products Market by Type
  3. 1.2.1 Global Human Blood Products Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immune Globulin
  5. 1.2.3 Coagulation Factor
  6. 1.2.4 Albumin
  7. 1.2.5 Other
  8. 1.3 Human Blood Products Market by Application
  9. 1.3.1 Global Human Blood Products Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Human Blood Products Market Dynamics
  1. 2.1 Human Blood Products Industry Trends
  2. 2.2 Human Blood Products Industry Drivers
  3. 2.3 Human Blood Products Industry Opportunities and Challenges
  4. 2.4 Human Blood Products Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Human Blood Products Market Perspective (2021-2032)
  2. 3.2 Global Human Blood Products Growth Trends by Region
  3. 3.2.1 Global Human Blood Products Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Blood Products Market Size by Region (2021-2026)
  5. 3.2.3 Global Human Blood Products Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Human Blood Products Revenue by Players
  2. 4.1.1 Global Human Blood Products Revenue by Players (2021-2026)
  3. 4.1.2 Global Human Blood Products Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Human Blood Products Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Blood Products Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Human Blood Products Key Players Headquarters & Area Served
  7. 4.4 Global Human Blood Products Players, Product Type & Application
  8. 4.5 Global Human Blood Products Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Human Blood Products Market CR5 and HHI
  11. 4.6.3 2025 Human Blood Products Tier 1, Tier 2, and Tier 3
5 Human Blood Products Market Size by Type
  1. 5.1 Global Human Blood Products Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Human Blood Products Revenue by Type (2021-2032)
  3. 5.3 Global Human Blood Products Revenue Market Share by Type (2021-2032)
6 Human Blood Products Market Size by Application
  1. 6.1 Global Human Blood Products Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Human Blood Products Revenue by Application (2021-2032)
  3. 6.3 Global Human Blood Products Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Biotest
  2. 7.1.1 Biotest Company Information
  3. 7.1.2 Biotest Business Overview
  4. 7.1.3 Biotest Human Blood Products Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Biotest Human Blood Products Product Portfolio
  6. 7.1.5 Biotest Recent Developments
  7. 7.2 BPL
  8. 7.2.1 BPL Company Information
  9. 7.2.2 BPL Business Overview
  10. 7.2.3 BPL Human Blood Products Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BPL Human Blood Products Product Portfolio
  12. 7.2.5 BPL Recent Developments
  13. 7.3 CSL
  14. 7.3.1 CSL Company Information
  15. 7.3.2 CSL Business Overview
  16. 7.3.3 CSL Human Blood Products Revenue and Gross Margin (2021-2026)
  17. 7.3.4 CSL Human Blood Products Product Portfolio
  18. 7.3.5 CSL Recent Developments
  19. 7.4 Grifols
  20. 7.4.1 Grifols Company Information
  21. 7.4.2 Grifols Business Overview
  22. 7.4.3 Grifols Human Blood Products Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Grifols Human Blood Products Product Portfolio
  24. 7.4.5 Grifols Recent Developments
  25. 7.5 Kedrion
  26. 7.5.1 Kedrion Company Information
  27. 7.5.2 Kedrion Business Overview
  28. 7.5.3 Kedrion Human Blood Products Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Kedrion Human Blood Products Product Portfolio
  30. 7.5.5 Kedrion Recent Developments
  31. 7.6 KM Biologics
  32. 7.6.1 KM Biologics Company Information
  33. 7.6.2 KM Biologics Business Overview
  34. 7.6.3 KM Biologics Human Blood Products Revenue and Gross Margin (2021-2026)
  35. 7.6.4 KM Biologics Human Blood Products Product Portfolio
  36. 7.6.5 KM Biologics Recent Developments
  37. 7.7 LFB Group
  38. 7.7.1 LFB Group Company Information
  39. 7.7.2 LFB Group Business Overview
  40. 7.7.3 LFB Group Human Blood Products Revenue and Gross Margin (2021-2026)
  41. 7.7.4 LFB Group Human Blood Products Product Portfolio
  42. 7.7.5 LFB Group Recent Developments
  43. 7.8 Octapharma
  44. 7.8.1 Octapharma Company Information
  45. 7.8.2 Octapharma Business Overview
  46. 7.8.3 Octapharma Human Blood Products Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Octapharma Human Blood Products Product Portfolio
  48. 7.8.5 Octapharma Recent Developments
  49. 7.9 Boya Bio
  50. 7.9.1 Boya Bio Company Information
  51. 7.9.2 Boya Bio Business Overview
  52. 7.9.3 Boya Bio Human Blood Products Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Boya Bio Human Blood Products Product Portfolio
  54. 7.9.5 Boya Bio Recent Developments
  55. 7.10 Hualan Bio
  56. 7.10.1 Hualan Bio Company Information
  57. 7.10.2 Hualan Bio Business Overview
  58. 7.10.3 Hualan Bio Human Blood Products Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Hualan Bio Human Blood Products Product Portfolio
  60. 7.10.5 Hualan Bio Recent Developments
  61. 7.11 Nanyue Bio
  62. 7.11.1 Nanyue Bio Company Information
  63. 7.11.2 Nanyue Bio Business Overview
  64. 7.11.3 Nanyue Bio Human Blood Products Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Nanyue Bio Human Blood Products Product Portfolio
  66. 7.11.5 Nanyue Bio Recent Developments
  67. 7.12 RAAS
  68. 7.12.1 RAAS Company Information
  69. 7.12.2 RAAS Business Overview
  70. 7.12.3 RAAS Human Blood Products Revenue and Gross Margin (2021-2026)
  71. 7.12.4 RAAS Human Blood Products Product Portfolio
  72. 7.12.5 RAAS Recent Developments
  73. 7.13 Shuanglin Bio
  74. 7.13.1 Shuanglin Bio Company Information
  75. 7.13.2 Shuanglin Bio Business Overview
  76. 7.13.3 Shuanglin Bio Human Blood Products Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Shuanglin Bio Human Blood Products Product Portfolio
  78. 7.13.5 Shuanglin Bio Recent Developments
  79. 7.14 CBPO
  80. 7.14.1 CBPO Company Information
  81. 7.14.2 CBPO Business Overview
  82. 7.14.3 CBPO Human Blood Products Revenue and Gross Margin (2021-2026)
  83. 7.14.4 CBPO Human Blood Products Product Portfolio
  84. 7.14.5 CBPO Recent Developments
  85. 7.15 Tiantan Bio
  86. 7.15.1 Tiantan Bio Company Information
  87. 7.15.2 Tiantan Bio Business Overview
  88. 7.15.3 Tiantan Bio Human Blood Products Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Tiantan Bio Human Blood Products Product Portfolio
  90. 7.15.5 Tiantan Bio Recent Developments
  91. 7.16 Weiguang Bio
  92. 7.16.1 Weiguang Bio Company Information
  93. 7.16.2 Weiguang Bio Business Overview
  94. 7.16.3 Weiguang Bio Human Blood Products Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Weiguang Bio Human Blood Products Product Portfolio
  96. 7.16.5 Weiguang Bio Recent Developments
  97. 7.17 Takeda
  98. 7.17.1 Takeda Company Information
  99. 7.17.2 Takeda Business Overview
  100. 7.17.3 Takeda Human Blood Products Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Takeda Human Blood Products Product Portfolio
  102. 7.17.5 Takeda Recent Developments
  103. 7.18 Yuanda Shuyang
  104. 7.18.1 Yuanda Shuyang Company Information
  105. 7.18.2 Yuanda Shuyang Business Overview
  106. 7.18.3 Yuanda Shuyang Human Blood Products Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Yuanda Shuyang Human Blood Products Product Portfolio
  108. 7.18.5 Yuanda Shuyang Recent Developments
8 North America
  1. 8.1 North America Human Blood Products Revenue (2021-2032)
  2. 8.2 North America Human Blood Products Revenue by Type (2021-2032)
  3. 8.2.1 North America Human Blood Products Revenue by Type (2021-2026)
  4. 8.2.2 North America Human Blood Products Revenue by Type (2027-2032)
  5. 8.3 North America Human Blood Products Revenue Share by Type (2021-2032)
  6. 8.4 North America Human Blood Products Revenue by Application (2021-2032)
  7. 8.4.1 North America Human Blood Products Revenue by Application (2021-2026)
  8. 8.4.2 North America Human Blood Products Revenue by Application (2027-2032)
  9. 8.5 North America Human Blood Products Revenue Share by Application (2021-2032)
  10. 8.6 North America Human Blood Products Revenue by Country
  11. 8.6.1 North America Human Blood Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Human Blood Products Revenue by Country (2021-2026)
  13. 8.6.3 North America Human Blood Products Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Human Blood Products Revenue (2021-2032)
  2. 9.2 Europe Human Blood Products Revenue by Type (2021-2032)
  3. 9.2.1 Europe Human Blood Products Revenue by Type (2021-2026)
  4. 9.2.2 Europe Human Blood Products Revenue by Type (2027-2032)
  5. 9.3 Europe Human Blood Products Revenue Share by Type (2021-2032)
  6. 9.4 Europe Human Blood Products Revenue by Application (2021-2032)
  7. 9.4.1 Europe Human Blood Products Revenue by Application (2021-2026)
  8. 9.4.2 Europe Human Blood Products Revenue by Application (2027-2032)
  9. 9.5 Europe Human Blood Products Revenue Share by Application (2021-2032)
  10. 9.6 Europe Human Blood Products Revenue by Country
  11. 9.6.1 Europe Human Blood Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Human Blood Products Revenue by Country (2021-2026)
  13. 9.6.3 Europe Human Blood Products Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Human Blood Products Revenue (2021-2032)
  2. 10.2 China Human Blood Products Revenue by Type (2021-2032)
  3. 10.2.1 China Human Blood Products Revenue by Type (2021-2026)
  4. 10.2.2 China Human Blood Products Revenue by Type (2027-2032)
  5. 10.3 China Human Blood Products Revenue Share by Type (2021-2032)
  6. 10.4 China Human Blood Products Revenue by Application (2021-2032)
  7. 10.4.1 China Human Blood Products Revenue by Application (2021-2026)
  8. 10.4.2 China Human Blood Products Revenue by Application (2027-2032)
  9. 10.5 China Human Blood Products Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Blood Products Revenue (2021-2032)
  2. 11.2 Asia Human Blood Products Revenue by Type (2021-2032)
  3. 11.2.1 Asia Human Blood Products Revenue by Type (2021-2026)
  4. 11.2.2 Asia Human Blood Products Revenue by Type (2027-2032)
  5. 11.3 Asia Human Blood Products Revenue Share by Type (2021-2032)
  6. 11.4 Asia Human Blood Products Revenue by Application (2021-2032)
  7. 11.4.1 Asia Human Blood Products Revenue by Application (2021-2026)
  8. 11.4.2 Asia Human Blood Products Revenue by Application (2027-2032)
  9. 11.5 Asia Human Blood Products Revenue Share by Application (2021-2032)
  10. 11.6 Asia Human Blood Products Revenue by Country
  11. 11.6.1 Asia Human Blood Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Human Blood Products Revenue by Country (2021-2026)
  13. 11.6.3 Asia Human Blood Products Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Blood Products Revenue (2021-2032)
  2. 12.2 SAMEA Human Blood Products Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Human Blood Products Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Human Blood Products Revenue by Type (2027-2032)
  5. 12.3 SAMEA Human Blood Products Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Human Blood Products Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Human Blood Products Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Human Blood Products Revenue by Application (2027-2032)
  9. 12.5 SAMEA Human Blood Products Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Human Blood Products Revenue by Country
  11. 12.6.1 SAMEA Human Blood Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Human Blood Products Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Human Blood Products Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst